The review also discusses expanding uses beyond cancer- such as CD19/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression, CAR-NK approaches targeting HIV, CAR-Tregs enhancing transplant tolerance, and senolytic CARs reducing tissue fibrosis. Here, CD19 is linked to systemic lupus erythematosus.